1. Louis CU, Shohet JM. Neuroblastoma: Molecular Pathogenesis and Therapy. Annu Rev Med. 2015;66:49–63.
2. Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol. 2001 Jan 12;54(12):897–910.
3. Speleman F, Park JR, Henderson TO. Neuroblastoma: A Tough Nut to Crack. Am Soc Clin Oncol Educ Book. 2016;35:e548-557.
4. Ngan ES-W. Heterogeneity of neuroblastoma. Oncoscience. 2015 Aug 24;2(10):837–8.
5. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines. Cancer Res. 2001 Aug 15;61(16):6185–93.
6. Owens C, Li BK, Thomas KE, Irwin MS. Surveillance imaging and radiation exposure in the detection of relapsed neuroblastoma. Pediatr Blood Cancer. 2016 Oct;63(10):1786–93.
7. Kotchetkov R, Cinatl J, Blaheta R, Vogel J-U, Karaskova J, Squire J, et al. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer. 2003 Mar 10;104(1):36–43.
8. Piskareva O, Harvey H, Nolan J, Conlon R, Alcock L, Buckley P, et al. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Lett. 2015 Aug 10;364(2):142–55.
9. Kothari A, Hittelman WN, Chambers TC. Cell cycle-dependent mechanisms underlie vincristine-induced death of primary acute lymphoblastic leukemia cells. Cancer Res. 2016 Jan 1;canres.2104.2015.
10. Smith V, Foster J. High-Risk Neuroblastoma Treatment Review. Children (Basel). 2018 Aug 28;5(9).
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74.
12. Groningen T van, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, et al. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nature Communications. 2019 Apr 4;10(1):1530.
13. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Reviews Clinical Oncology. 2017 Oct;14(10):611–29.
14. Tanabe S, Quader S, Cabral H, Ono R. Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies. Front Pharmacol [Internet]. 2020 [cited 2021 Mar 10];11. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2020.00904/full
15. Venkatesh V, Nataraj R, Thangaraj GS, Karthikeyan M, Gnanasekaran A, Kaginelli SB, et al. Targeting Notch signalling pathway of cancer stem cells. Stem Cell Investigation [Internet]. 2018 Mar 12 [cited 2021 Feb 14];5(3). Available from: https://sci.amegroups.com/article/view/18689
16. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nature Reviews Neuroscience. 2006 Feb;7(2):93–102.
17. Aster JC, Pear WS, Blacklow SC. The Varied Roles of Notch in Cancer. Annu Rev Pathol Mech Dis. 2017 Jan 24;12(1):245–75.
18. Bolós V, Grego-Bessa J, de la Pompa JL. Notch Signaling in Development and Cancer. Endocrine Reviews. 2007 May 1;28(3):339–63.
19. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014 Sep 5;6(3):1769–92.
20. Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L, et al. SOX2 Gene Regulates the Transcriptional Network of Oncogenes and Affects Tumorigenesis of Human Lung Cancer Cells. PLOS ONE. 2012 May 15;7(5):e36326.
21. Ongaratti BR, Silva CBO, Trott G, Haag T, Leães CGS, Ferreira NP, et al. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. Braz J Med Biol Res [Internet]. 2016 Mar 18 [cited 2019 Oct 19];49(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819410/
22. Kang KW, Im YB, Go W-J, Han H-K. c-Myc Amplification Altered the Gene Expression of ABC- and SLC-Transporters in Human Breast Epithelial Cells. Mol Pharmaceutics. 2009 Apr 6;6(2):627–33.
23. Somasundaram DB, Aravindan S, Yu Z, Jayaraman M, Tran NTB, Li S, et al. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples. BMC Cancer. 2019 Jan 28;19(1):106.
24. Westermann F, Muth D, Benner A, Bauer T, Henrich K-O, Oberthuer A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 2008;9(10):R150.
25. Cotterman R, Knoepfler PS. N-Myc Regulates Expression of Pluripotency Genes in Neuroblastoma Including lif, klf2, klf4, and lin28b. PLoS One [Internet]. 2009 Jun 4 [cited 2019 Oct 19];4(6). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686170/
26. Varlakhanova NV, Cotterman RF, deVries WN, Morgan J, Donahue LR, Murray S, et al. myc maintains embryonic stem cell pluripotency and self-renewal. Differentiation. 2010 Jul;80(1):9–19.
27. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci USA. 2010 Aug 10;107(32):14152–7.
28. Mukherjee P, Gupta A, Chattopadhyay D, Chatterji U. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells. Sci Rep [Internet]. 2017 Aug 23;7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569040/
29. Timmerman LA, Grego-Bessa J, Raya A, Bertrán E, Pérez-Pomares JM, Díez J, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004 Jan 1;18(1):99–115.
30. Saad S, Stanners SR, Yong R, Tang O, Pollock CA. Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor. Int J Biochem Cell Biol. 2010 Jul;42(7):1115–22.
31. Chen J, Imanaka N, Chen J, Griffin JD. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. British Journal of Cancer. 2010 Jan;102(2):351–60.
32. Zhang L, Sha J, Yang G, Huang X, Bo J, Huang Y. Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells. Cell Cycle. 2017 May 19;16(10):999–1007.
33. Yang J, Guo W, Wang L, Yu L, Mei H, Fang S, et al. Notch signaling is important for epithelial-mesenchymal transition induced by low concentrations of doxorubicin in osteosarcoma cell lines. Oncol Lett. 2017 Apr;13(4):2260–8.
34. Ma L, Dong P, Liu L, Gao Q, Duan M, Zhang S, et al. Overexpression of protein O-fucosyltransferase 1 accelerates hepatocellular carcinoma progression via the Notch signaling pathway. Biochem Biophys Res Commun. 2016 Apr 29;473(2):503–10.
35. Pancewicz-Wojtkiewicz J, Eljaszewicz A, Kowalczuk O, Niklinska W, Charkiewicz R, Kozłowski M, et al. Prognostic significance of Notch ligands in patients with non-small cell lung cancer. Oncol Lett. 2017 Jan;13(1):506–10.
36. Bettinsoli P, Ferrari-Toninelli G, Bonini SA, Prandelli C, Memo M. Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma. BMC Cancer [Internet]. 2017 May 19;17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438559/
37. Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, et al. Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications. 2018 Oct 8;9(1):4121.
38. Li Q-Q, Xu J-D, Wang W-J, Cao X-X, Chen Q, Tang F, et al. Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells. Clin Cancer Res. 2009 Apr 15;15(8):2657–65.
39. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 2006 Aug 25;126(4):663–76.
40. Müller M, Hermann PC, Liebau S, Weidgang C, Seufferlein T, Kleger A, et al. The role of pluripotency factors to drive stemness in gastrointestinal cancer. Stem Cell Research. 2016 Mar 1;16(2):349–57.
41. Tian T, Zhang Y, Wang S, Zhou J, Xu S. Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J Biomed Res. 2012 Sep;26(5):336–45.
42. Teng R, Hu Y, Zhou J, Seifer B, Chen Y, Shen J, et al. Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. PLOS ONE. 2015 Dec 4;10(12):e0143716.
43. Pu Y, Zhao F, Wang H, Cai S. MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. Scientific Reports. 2017 Mar 10;7:44218.
44. Lim S, Becker A, Zimmer A, Lu J, Buettner R, Kirfel J. SNAI1-Mediated Epithelial-Mesenchymal Transition Confers Chemoresistance and Cellular Plasticity by Regulating Genes Involved in Cell Death and Stem Cell Maintenance. PLoS One [Internet]. 2013 Jun 17 [cited 2019 Oct 20];8(6). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684605/
45. Tsou S-H, Chen T-M, Hsiao H-T, Chen Y-H. A Critical Dose of Doxorubicin Is Required to Alter the Gene Expression Profiles in MCF-7 Cells Acquiring Multidrug Resistance. PLOS ONE. 2015 Jan 30;10(1):e0116747.
46. Prieto-Vila M, Takahashi R, Usuba W, Kohama I, Ochiya T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. International Journal of Molecular Sciences. 2017 Dec 1;18(12):2574.
47. Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013 Jul 1;34(7):1420–30.
48. Groningen T van, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nature Genetics. 2017 Aug;49(8):1261–6.